CD274 and neoplasm: In contrast, in the KEYNOTE 045 study, a significant difference in OS was observed in favour of the anti-PD-1 pembrolizumab versus chemotherapy in patients with high PD-L1 tumours defined as CPS according the 22C3 Dako assay [57].